TM-38837

Last updated
TM-38837
TM-38837 (corrected).svg
Identifiers
  • 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(2H-tetrazol-5-ylmethyl)-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]pyrazole-3-carboxamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Formula C27H20Cl2F3N7O
Molar mass 586.40 g·mol−1
3D model (JSmol)
  • ClC(C=C1)=C(C=C1)N(N=C1C(=O)N[C@H](C)C(C=CC2C(F)(F)F)=CC=2)C(=C1CC(N=N1)=NN1)C(C=CC1Cl)=CC=1
  • InChI=1S/C27H20Cl2F3N7O/c1-15(16-6-10-18(11-7-16)27(30,31)32)33-26(40)24-20(14-23-34-37-38-35-23)25(17-8-12-19(28)13-9-17)39(36-24)22-5-3-2-4-21(22)29/h2-13,15H,14H2,1H3,(H,33,40)(H,34,35,37,38)/t15-/m1/s1
  • Key:DANBLBWVACCFGQ-OAHLLOKOSA-N

TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. [1] The company has announced phase I clinical trials.

Contents

TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as rimonabant. The structure of TM-38837 has been erronously referred to in the past as compound 8 in reference [2] but is now known from a more recent reference. [3]

See also

References

  1. ↑ "7TM Pharma". Archived from the original on July 7, 2011. Retrieved January 18, 2011.
  2. ↑ Hung MS, Chang CP, Li TC, Yeh TK, Song JS, Lin Y, et al. (September 2010). "Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist". ChemMedChem. 5 (9): 1439–1443. doi: 10.1002/cmdc.201000246 . PMID   20652930. S2CID   34244587.
  3. ↑ Cooper ME, Nørregaard PK, Andersson G, Linget JM, Högberg T, Little PB, Receveur JM, Elling CE (December 2025). "Efficacy of the Hepatotropic Peripheral CB1R Inverse Agonist TM38837 in Rat Models of Obesity and Metabolic Syndrome". J. Mol. Clin. Med. 8 (1) 36687. doi: 10.31083/jmcm36687 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.